Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method for the treatment of cerebral ischaemia and use of erythropoietin or erythropoietin derivatives for the treatment of cerebral ischaemia

a technology of erythropoietin and cerebral ischaemia, which is applied in the field of method the use of erythropoietin or erythropoietin derivatives for the can solve the problem of no effective treatment of cerebral ischaemia

Inactive Publication Date: 2009-04-07
EHRENREICH HANNELORE +1
View PDF25 Cites 34 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

To date there is no effective therapy for cerebral ischaemia, such as for example for the treatment of stroke patients without operating on the head region of the patient.
Because of the knowledge that the blood brain barrier cannot be surmounted by larger proteins, erythropoietin is administered directly to the brain tissue, i.e. by direct infusion, in experiments; however such direct infusion is ruled out in humans because of the high risks which are associated with the application and the maintenance of a temporary ventricle drainage, for example of infections or bleeding.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for the treatment of cerebral ischaemia and use of erythropoietin or erythropoietin derivatives for the treatment of cerebral ischaemia
  • Method for the treatment of cerebral ischaemia and use of erythropoietin or erythropoietin derivatives for the treatment of cerebral ischaemia

Examples

Experimental program
Comparison scheme
Effect test

examples

[0026]In FIG. 1A, the average of the serum concentration of four patients with strokes, i.e. whose peripheral concentration of erythropoietin is measured over several days to whom at approximately 8 hours, approximately 24 hours and again approximately 48 hours after the stroke were given respectively a dose of 35,000 IE human recombinant erythropoietin (preparation “Neorecormon” by the Hoffmann LaRoche AG company) intravenously. It can be detected that the serum concentration achieves its maximum within the first few days and then decreases sharply subsequently.

[0027]In FIG. 1B, the concentrations of EPO are represented in six control patients with non-ischaemic neurological illnesses (“neurological disease controls”) after infusion of erythropoietin, in two untreated stroke patients (“stroke controls”) without infusion of erythropoietin and also in four stroke patients (“EPO patients”) after infusion of erythropoietin as in the case of the control patients. There is represented th...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a method for the treatment of cerebral ischaemia and a drug for the treatment of cerebral ischaemia in particular in humans, as occurs for example in the case of stroke patients. It was found surprisingly that peripheral administering of erythropoietin to the cerebral tissue affected by the ischaemia has a distinctly protective effect. Erythropoietin has the effect thereby that the region of the cerebral tissue which is damaged permanently, in particular in the penumbra, is dramatically reduced relative to conventional measures in the case of cerebral ischaemia without erythropoietin administration.

Description

CROSS REFERENCE TO RELATED PATENT APPLICATIONS[0001]This patent application claims the benefit of PCT Application No. PCT / EP99 / 09864, filed on Dec. 13, 1999, which claims priority to German patent application 198 57 609.9 filed on Dec. 14, 1998.FIELD OF THE INVENTION[0002]The present invention relates to a method for the treatment of cerebral ischaemia and a drug for the treatment of cerebral ischaemia in mammals, in particular in humans, such as occur for example in the case of stroke patients.BACKGROUND OF THE INVENTION[0003]In the case of an ischaemic brain infarction, the damaged regions are divided into the ischaemic core zone and the so-called penumbra which surrounds the core. The size of the ischaemic core plus penumbra determines the extent of the damage after ischaemic insult.[0004]Erythropoietin, also called “EPO” for short, is a glycoprotein which occurs naturally in the body with a molecular weight of 30,000 Dalton (W. Jelkman, “Erythropoietin: Structure, Control of Pro...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/18A61K45/00A61K38/22A61P9/10
CPCA61K38/1816A61P25/00A61P9/00A61P9/10A61K38/22
Inventor EHRENREICH, HANNELOREGLEITER, CHRISTOPH
Owner EHRENREICH HANNELORE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com